文献速递泌尿生殖MRUS

MRI-超声融合引导与系统穿刺活检在前列腺癌中的准确性

Accuracy of MRI-ultrasound fusion-guided and systematic biopsy of the prostate.
PubMed 文献 · Br J Radiol · 2024-01-01

该研究纳入2013年1月1日至2022年6月1日间867例接受系统与靶向穿刺活检的患者,按PI-RADS≥3为活检阈值。联合活检对临床显著前列腺癌检出最准确(P < .001),靶向活检单独检出率43.1% vs 系统活检单独40.3%(P = .046)。对于后部PI-RADS 5病变,各活检方法间无统计学显著差异,作者提示系统活检可保留用于靶向活检结果阴性时。

要点

  • 联合系统与靶向活检对临床显著前列腺癌检出最准确(P < .001)。
  • 靶向活检单独检出临床显著癌43.1%,高于系统活检单独的40.3%(P = .046)。
  • 后部PI-RADS 5病变各活检方法间无统计学显著差异。

核心结论

  • 在临床显著前列腺癌检出中,系统与靶向活检联合最为有效;后部PI-RADS 5病变靶向活检很少漏诊显著癌,作者提示系统活检可保留用于靶向活检结果阴性时。

研究设计与样本

  • 研究纳入2013年1月1日至2022年6月1日间867例活检初治或既往活检阴性且同时接受系统与靶向活检的患者;MRI按PI-RADS评估,活检阈值设为PI-RADS ≥3;系统活检根据前列腺体积取8-12针;采用McNemar检验比较活检类型。

诊断标准与关键数值

  • 总体前列腺癌检出率:PI-RADS 3为48%、PI-RADS 4为72%、PI-RADS 5为90%;临床显著前列腺癌(Gleason评分≥3+4)检出率分别为21%、53%、72%;靶向活检单独检出临床显著癌43.1% vs 系统活检单独40.3%(P = .046);联合活检检出临床显著癌最准确(P < .001)。

临床应用与阅片要点

  • 作者认为,对于后部PI-RADS 5病变,系统活检可保留用于靶向活检结果阴性时;联合活检对临床显著前列腺癌检出最有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Prostate multiparametric MRI (mpMRI) with subsequent targeted biopsy of suspicious lesions has a critical role in the diagnostic workup of prostate cancer. The objective was to evaluate the diagnostic accuracy of systematic biopsies, targeted biopsies, and the combination of both in prostate cancer detection.

METHODS: From January 1, 2013 to June 1, 2022, biopsy-naïve and prior biopsy-negative patients who underwent both systematic and targeted biopsies were included. MRIs were evaluated according to PI-RADS with biopsy threshold set at PI-RADS ≥3. Systematic biopsies consisted of 8-12 cores, based on prostate volume. Overall prostate cancer and clinically significant cancer (Gleason Score ≥3 + 4) detection rates were stratified based on PI-RADS and location within the prostate, and compared between biopsy types using McNemar test.

RESULTS: Among 867 patients, 615 had prostate cancer, with 434 clinically significant cases. Overall detection rates were: PI-RADS 3 48%, PI-RADS 4 72%, and PI-RADS 5 90%. Detection rates for clinically significant cancer were 21%, 53%, and 72%, respectively. The combination of biopsy methods was most accurate in detecting clinically significant prostate cancer (P < .001). Targeted biopsies alone detected more clinically significant prostate cancer than systematic biopsies alone (43.1% vs 40.3%, P = .046). For posterior PI-RADS 5 lesions, no statistically significant difference was found between all biopsy methods.

CONCLUSIONS: In the detection of clinically significant prostate cancer, the combination of systematic and targeted biopsies proves most effective. Targeted biopsies rarely missed significant cancer for posterior PI-RADS 5 lesions, suggesting systematic biopsies could be reserved for instances where targeted biopsy results are negative.

ADVANCES IN KNOWLEDGE: This study emphasizes on the efficacy of mpMRI and targeted biopsies in suspected prostate cancer in real-world clinical context. For PI-RADS 5 lesions, systematic biopsies provide limited clinical benefit and may only be necessary when targeted biopsy results are negative.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. In de Braekt T, van Rooij SBT, Daniels-Gooszen AW, et al. Accuracy of MRI-ultrasound fusion-guided and systematic biopsy of the prostate. Br J Radiol. 2024. PMID: 38627253. doi:10.1093/bjr/tqae080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。